Elagolix (Orilissa) Use in Special Populations

Elagolix (Orilissa) Use in Special Populations

Elagolix is absolutely contraindicated during pregnancy, as animal studies and clinical evidence suggest an increased risk of early pregnancy loss. If you are trying to conceive or are already pregnant, you must not take this medication. Because elagolix may alter menstrual patterns (irregular, reduced, or absent bleeding), this can make it difficult to recognize pregnancy; therefore, be alert to other early signs of pregnancy, such as breast tenderness, weight gain, nausea, etc. If pregnancy is suspected, stop the drug immediately and contact your doctor. In addition, elagolix does not act as a contraceptive. You must use effective non-hormonal contraception, such as condoms or spermicides, during treatment and for 28 days after stopping the drug. Combined oral contraceptives containing estrogen may interact with elagolix and reduce its efficacy, so your doctor may recommend switching contraceptive methods; adequate data on the concomitant use of elagolix with progestin‑only contraceptives (e.g., implants, injectables) are also lacking, so caution is advised. For breastfeeding women, it is unknown whether elagolix is excreted in human milk; therefore, the benefits and risks should be weighed under medical guidance to decide whether to breastfeed or adjust the medication. If accidental pregnancy occurs during treatment, you are encouraged to enroll in the pregnancy registry (phone 1-833-782-7241) to collect maternal and infant health information and help improve the drug safety database.

Elagolix (Orilissa) Administration, Dosage, and Missed Dose Management

Elagolix is an oral tablet available in two strengths: 150 mg (light blue) and 200 mg (white). The 150 mg dose is taken once daily, one tablet each day, preferably at a fixed time each day; the 200 mg dose is taken twice daily, one tablet each time (total daily dose 400 mg), also at fixed intervals (e.g., morning and evening). Both tablets can be taken with or without food, as food does not affect absorption. Please strictly follow your doctor's instructions; do not stop or reduce the dose on your own even if pain improves, because continuous estrogen suppression is required to maintain efficacy. If you forget a dose: if you remember on the same day, take it as soon as possible; if more than one day has passed, skip the missed dose and take the next dose at the usual time. Never take a double dose to make up for a missed one. For the 150 mg strength, do not exceed 1 tablet per day; for the 200 mg strength, do not exceed 2 tablets (400 mg) per day. Overdosing may increase the risk of adverse reactions; if it occurs, contact your gynecologist immediately or go to the emergency department. Store the medication at room temperature between 36°F and 86°F (2°C–30°C), and keep it out of the reach of children. After stopping treatment, menstruation usually returns within 1 to 6 months, but the exact time varies among individuals.

Serious Side Effects of Elagolix (Orilissa)

In addition to bone loss and pregnancy risks, elagolix may cause two other serious adverse reactions that require high vigilance. First, suicidal ideation and behavior: in phase 2/3 clinical studies involving 2,090 women, 4 reported suicidal thoughts, 2 of whom discontinued treatment, and 1 died by suicide (the investigator attributed this to life‑stress events). Therefore, if you experience new or worsening depression, anxiety, suicidal thoughts, behavioral abnormalities, or severe mood fluctuations during treatment, seek medical attention immediately. Close monitoring is especially important in patients with a history of depression or those taking antidepressants (in this population, 19% had a history of depression and 13% were on antidepressants at enrollment). Second, liver injury: elagolix may cause abnormal liver function tests. If you develop jaundice (yellowing of skin or eyes), dark urine, fatigue, nausea/vomiting, generalized edema, right upper quadrant pain, or easy bruising, contact your doctor immediately. In addition, this drug is contraindicated in patients with severe hepatic impairment and in those taking strong OATP1B1 inhibitors (which can significantly increase elagolix blood levels). Although these serious events are rare, patients and caregivers should be fully informed and remain alert during treatment. Do not ignore early warning signs; seek help from healthcare professionals promptly if you experience any discomfort or mood changes.